Appili Therapeutics

ACOA awards Appili Therapeutics $2.8M for clinical trials

Tuesday, February 21, 2017

Appili Therapeutics, an anti-infective drug development company, announced that it will be receiving $2,803,148 from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable Appili to take its first drug, ATI-1501—a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile—through clinical trials to be ready for market approval.

[Read More]